慢性粒细胞白血病(CML)是一种发生在多功能造血干细胞的主要涉及髓系的恶性骨髓增殖性肿瘤,简称慢粒。慢粒治疗应着重于慢性期早期,尽快获得细胞遗传学以及分子生物学水平的缓解,避免疾病转化,进入进展期的患者常常预后不佳。慢粒慢性...慢性粒细胞白血病(CML)是一种发生在多功能造血干细胞的主要涉及髓系的恶性骨髓增殖性肿瘤,简称慢粒。慢粒治疗应着重于慢性期早期,尽快获得细胞遗传学以及分子生物学水平的缓解,避免疾病转化,进入进展期的患者常常预后不佳。慢粒慢性期患者治疗首选酪氨酸激酶抑制剂(TKI),TKI极大地改善了疾病地整体预后,使绝大多数患者生存期接近正常人。本文主要对TKI在CML的应用进展进行综述。CML is a malignant myeloproliferative tumor occurring in multifunctional hematopoietic stem cells, mainly involving the myeloid lineage. The treatment of CML should focus on the early chronic phase, avoid disease transformation, obtain cytogenetic and molecular remission as soon as possible. Once in the progressive phase, the patients may have a poor prognosis. TKI is the first choice for treatment in chronic patients. With the development of TKI, the course of CML has changed greatly, and the survival of most patients is close to normal people. This paper mainly reviews the application progress of TKI in CML.展开更多
文摘慢性粒细胞白血病(CML)是一种发生在多功能造血干细胞的主要涉及髓系的恶性骨髓增殖性肿瘤,简称慢粒。慢粒治疗应着重于慢性期早期,尽快获得细胞遗传学以及分子生物学水平的缓解,避免疾病转化,进入进展期的患者常常预后不佳。慢粒慢性期患者治疗首选酪氨酸激酶抑制剂(TKI),TKI极大地改善了疾病地整体预后,使绝大多数患者生存期接近正常人。本文主要对TKI在CML的应用进展进行综述。CML is a malignant myeloproliferative tumor occurring in multifunctional hematopoietic stem cells, mainly involving the myeloid lineage. The treatment of CML should focus on the early chronic phase, avoid disease transformation, obtain cytogenetic and molecular remission as soon as possible. Once in the progressive phase, the patients may have a poor prognosis. TKI is the first choice for treatment in chronic patients. With the development of TKI, the course of CML has changed greatly, and the survival of most patients is close to normal people. This paper mainly reviews the application progress of TKI in CML.
